Johnson & Johnson (JNJ) transition underway, UBS assesses upcoming analyst day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to Johnson & Johnson (JNJ) transition underway, UBS assesses upcoming analyst day
November 30, 2023 4:30 PM EST
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--
Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors.
Mr. Woods is an exceptional addition to Johnson & Johnsons Board of Directors, said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. Mr. Woods has an impressive career of leading and transforming healthcare systems while prioritizing the delivery of high-quality, equitable patient care. The Board looks forward to working with him as the Company continues to focus on healthcare... More
November 30, 2023 8:40 AM EST
Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation
Strengthens position in high-growth MedTech segments
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--
Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory... More
